# Multicultural Community Dementia Screening

> **NIH NIH R01** · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · 2024 · $2,627,226

## Abstract

ABSTRACT
The US Preventative Services Task Force (USPSTF) concluded that current evidence is insufficient to assess the
balance of benefits vs harms of screening for mild cognitive impairment (MCI) and early Alzheimer's disease and
related disorders (ADRD), first published in 2014 and recently updated. Instead, the USPSTF has called for more
research, publishing a research plan in 2017 to evaluate the evidence of dementia screening. Community
detection of MCI and early ADRD may be limited due to the lack of screening tests characterizing the earliest
signs of impairment, monitoring response to interventions, correspondence to biomarkers, and the potential
benefits versus harms from screening. The inability to detect MCI and ADRD may affect eligibility determination
for care and services, and impede case ascertainment and recruitment in clinical research. In our prior 5-year
funding cycle, we asked important questions regarding (a) the best methods to screen, (b) effective of these
methods across relevant biological variables (age, sex, race, and ethnicity), (c) how measures correspond to “Gold
Standard” evaluations, and (d) what individuals do with results. Our overarching GOAL of the current proposed
investigation is to address the major challenges to improve the detection of MCI and early ADRD. We emphasize
deep phenotyping—the acquisition of multiple types of data from the same individual repeated over time from
multiple individuals. Although interested in broader MCI/ADRD detection, we leverage the amyloid, tau,
neurodegeneration (ATN) research framework to anchor this work, particularly how biomarkers and relevant
biological variables (e.g., age, sex, race, ethnicity) explain differential risk for transition across the ATN
Framework stages. To do this, we propose 3 SPECIFIC AIMS: (1) Determine population-based MCI/ADRD
prevalence in 2500 adults age 55+ enrolled in Florida Blue Cross medical insurance (total sampling frame: 5.2
million) using a novel on-line evaluation; (2) Recruit 500 individuals from Aim 1 for annual in-person
comprehensive visits with deep phenotyping to determine the accuracy of on-line evaluation against longitudinal
cognitive, fluid, genetic, MRI, and amyloid and tau PET imaging biomarkers, and evaluate the ability of baseline
measures to predict longitudinal cognitive decline and transition across NIA-AA stages and by relevant biological
variables; and (3) Define the benefits vs. harms of MCI/ADRD screening by testing improved decision-making
(advance care planning, medications), patient-centered (health-related quality of life, physical functionality,
health care utilization) and caregiver-centered outcomes (burden, strain, mood, health-related quality of life) in
the longitudinal cohort characterized in Aim 2. Our long-term goal is to increase “real world” early MCI and ADRD
detection, diagnosis, and treatment; address USPSTF Key Questions; and reduce disparities in health outcomes. This
resonates strongly with the t...

## Key facts

- **NIH application ID:** 10834005
- **Project number:** 5R01AG071514-04
- **Recipient organization:** UNIVERSITY OF MIAMI SCHOOL OF MEDICINE
- **Principal Investigator:** James E Galvin
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $2,627,226
- **Award type:** 5
- **Project period:** 2021-05-01 → 2026-01-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10834005

## Citation

> US National Institutes of Health, RePORTER application 10834005, Multicultural Community Dementia Screening (5R01AG071514-04). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/10834005. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*